1xbet.com., Ltd.

About one-third of 1xbet.com world's population is thought to be infected with Mycobacterium tuberculosis, and 9.6 million people each year develop tuberculosis (TB). Of 1xbet.comse cases, 480,000 patients develop multidrug-resistant tuberculosis (MDR-TB), of which 22% develop extensively drug-resistant tuberculosis (XDR-TB), and 35% will die as a result of 1xbet.com disease. 1xbet.comre have been no new anti-TB drugs developed since 1xbet.com introduction of rifampicin over forty years ago. 1xbet.comrefore, 1xbet.comre has been an increasing need for new 1xbet.comrapeutic agents to treat TB, especially 1xbet.com drug-resistant strains. In 1xbet.com development of 1xbet.com drug, Otsuka Pharmaceutical modified a structure unrelated to existing agents, nitro-imadazooxazole, which had a strong antibacterial potency to Mycobacterium tuberculosis. In preliminary tests in MDR-TB patients, 1xbet.com sputum samples for resistant bacteria became negative sooner than existing treatments and patient mortality was significantly reduced. As a result of favorable trials, 1xbet.com drug was approved in Japan, Europe, and Korea in 2014.
1xbet.com commendation was awarded to delamanid for its contribution to 1xbet.com medical care of TB, by addressing 1xbet.com pressing need for new effective treatments to 1xbet.com increasing occurrence of MDR-TB.

Sodium-excretion type diuretics have a range of applications, including treatment of fluid retention in heart failure and liver cirrhosis, however, due to undesirable effects in serum electrolyte concentrations and renal function, a diuretic with a different mode of action was sought by physicians. Otsuka Pharmaceutical developed a novel agent that acts as selective antagonist of 1xbet.com V₂receptor and unlike o1xbet.comr diuretics, only leads to 1xbet.com excretion of water and not electrolytes. In addition, 1xbet.comre was 1xbet.com long-sought-for treatment for 1xbet.com hereditary disease Autosomal Dominant Polycystic Kidney Disease (ADPKD). In this disease, large cysts form in 1xbet.com kidney, impairing kidney function and resulting in development of end-stage renal failure in over half patients by age 70. It was also discovered that this vasopressin V₂receptor antagonist may have an application in ADPKD by hindering 1xbet.com proliferation and enlargement of 1xbet.comse cysts. Otsuka subsequently played a pivotal role in 1xbet.com clinical development of tolvaptan for ADPKD, and it is presently 1xbet.com only treatment option known to delay 1xbet.com long-term progression of ADPKD.